Protease inhibitor risks may be greater for HIV-positive cancer patients

09/13/2013 | MedPage Today (free registration)

People with cancer who were HIV-positive and received antiretroviral treatment based on protease inhibitors reported more adverse events than those treated with integrase inhibitor- or non-nucleoside reverse transcriptase inhibitor-based medications, an analysis found. Six-month efficacy of the protease inhibitor-based regimen was lower than with the other two treatment options. The findings were presented at the Interscience Conference on Anti-Microbial Agents and Chemotherapy.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI